Search Result

Results for "

viral infectivity

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Antibiotic (6) Apoptosis (2) Bacterial (5) CMV (1) COX (5) Cytochrome P450 (2) Eukaryotic Initiation Factor (eIF) (1) Glucocorticoid Receptor (2) HCV Protease (2) HIV (3) Influenza Virus (10) Isotope-Labeled Compounds (3) Orthopoxvirus (2) SARS-CoV (7)
By Research Areas:	Cancer (9) Infection (14) Inflammation/Immunology (11) Metabolic Disease (4) Neurological Disease (1)
Click Chemistry:	Azide (1)

Inhibitors & Agonists

Screening Libraries

Fluorescent Dye

Biochemical Assay Reagents

Natural
Products

Isotope-Labeled Compounds

Click Chemistry

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-141841

SARS-CoV-2-IN-7

SARS-CoV Infection

SARS-CoV-2-IN-7 inhibits viral replication with a nanomolar IC₅₀ value (844 nM) in SARS-CoV-2-infected Vero E6 cells.

SARS-CoV-2-IN-7	SARS-CoV	Infection
SARS-CoV-2-IN-7 inhibits viral replication with a nanomolar IC₅₀ value (844 nM) in SARS-CoV-2-infected Vero E6 cells.

HY-N0677

Dehydroandrographolide succinate	Influenza Virus	Infection Inflammation/Immunology Cancer
Dehydroandrographolide succinate, extracted from herbal medicine Andrographis paniculata (Burm f) Nees, is widely used for the treatment of viral pneumonia and viral upper respiratory tract infections because of its immunostimulatory, anti-infective and anti-inflammatory effect .

HY-100442

Paquinimod 10+ Cited Publications ABR-215757; ABR 25757	SARS-CoV	Metabolic Disease Inflammation/Immunology
Paquinimod (ABR 215757) is a specific and orally active inhibitor of S100A8/S100A9. Paquinimod rescues the pneumonia with substantial reduction of viral loads in SARS-CoV-2-infected mice .

HY-N12840

Logmalicid B

Others Metabolic Disease

Logmalicid B is an iridoid glycoside compound that can be isolated from Cornus officinalis and can be used in diabetes research .

Logmalicid B	Others	Metabolic Disease
Logmalicid B is an iridoid glycoside compound that can be isolated from Cornus officinalis and can be used in diabetes research .

HY-120157

Vif-ElonginC interaction inhibitor 1	HIV	Infection
Vif-ElonginC interaction inhibitor 1 (compound VEC-5) is a potent Vif inhibitor. Vif-ElonginC interaction inhibitor 1 can restrict HIV-1 in Vif-nonpermissive cells. Vif-ElonginC interaction inhibitor 1 can protect A3G, APOBEC3C (A3C), and APOBEC3F (A3F) from Vif-mediated degradation and drastically inhibit Vif function through blocking the interaction between Vif and ElonginC. Vif-ElonginC interaction inhibitor 1 enhances A3G incorporation into HIV-1 virions to reduce viral infectivity .

HY-102014

RN-18

HIV Infection

RN-18 is a HIV-1 viral infectivity factor (HIV-1 Vif) inhibitor with an IC₅₀ of 6 μM in nonpermissive H9 cells.

RN-18	HIV	Infection
RN-18 is a HIV-1 viral infectivity factor (HIV-1 Vif) inhibitor with an IC₅₀ of 6 μM in nonpermissive H9 cells.

HY-N0677A

Kalii Dehydrographolidi Succinas Potassium dehydroandrographolide succinate	Antibiotic	Infection Inflammation/Immunology Cancer
Kalii Dehydrographolidi Succinas (Potassium dehydroandrographolide succinate), extracted from herbal medicine Andrographis paniculata (Burm f) Nees, is widely used for the treatment of viral pneumonia and viral upper respiratory tract infections because of its immunostimulatory, anti-infective and anti-inflammatory effect .

HY-100442S

Paquinimod-d5 ABR-215757-d₅; ABR 25757-d₅	SARS-CoV Isotope-Labeled Compounds	Metabolic Disease
Paquinimod-d5 is a deuterated analog of Paquinimod (HY-100442). Paquinimod (ABR 215757) is a specific and orally active inhibitor of S100A8/S100A9. Paquinimod rescues the pneumonia with substantial reduction of viral loads in SARS-CoV-2-infected mice .

HY-N7922

Urolithin M5 Decarboxyellagic acid	Influenza Virus	Infection
Urolithin M5 is a neuraminidase inhibitor that can be isolated from Ganlanye. Urolithin M5 has antiviral activity in vitro and in vivo by inhibiting the activity of viral NA. Urolithin M5 can increase the survival rate and improve pulmonary edema in pr8-infected mouse models. Urolithin M5 can be used in anti-influenza research .

HY-100442S1

Paquinimod-d5-1 ABR-215757-d₅-1; ABR 25757-d₅-1	SARS-CoV Isotope-Labeled Compounds	Metabolic Disease Inflammation/Immunology
Paquinimod-d5-1 is a deuterated analog of Paquinimod (HY-100442). Paquinimod (ABR 215757) is a specific and orally active inhibitor of S100A8/S100A9. Paquinimod rescues the pneumonia with substantial reduction of viral loads in SARS-CoV-2-infected mice .

HY-147014

Cyclic HPMPC	CMV Orthopoxvirus	Infection
Cyclic HPMPC is a potent antiviral agent. Cyclic HPMPC can increase arterial oxygen saturation levels in lethal vaccinia virus (IHD strain)-infected mice. Cyclic HPMPC improves the outcome of congenital guinea pig cytomegalovirus (GPCMV) infection and decreases viral replication in guinea pig model .

HY-14397

Indomethacin Maximum Cited Publications 33 Publications Verification Indometacin	COX Antibiotic Influenza Virus Bacterial	Inflammation/Immunology Cancer
Indomethacin (Indometacin) is a potent, orally active COX1/2 inhibitor with IC₅₀ values of 18 nM and 26 nM for COX-1 and COX-2, respectively. Indomethacin has anticancer activity and anti-infective activity. Indomethacin can be used for cancer, inflammation and viral infection research .

HY-15034

Indomethacin sodium Indometacin sodium	COX Antibiotic Influenza Virus Bacterial	Inflammation/Immunology Cancer
Indomethacin (Indometacin) sodium is a potent, orally active COX1/2 inhibitor with IC₅₀ values of 18 nM and 26 nM for COX-1 and COX-2, respectively. Indomethacin sodium has anticancer activity and anti-infective activity. Indomethacin sodium can be used for cancer, inflammation and viral infection research. .

HY-14397A

Indomethacin sodium hydrate Maximum Cited Publications 33 Publications Verification Indometacin sodium hydrate	COX Bacterial Influenza Virus Antibiotic	Inflammation/Immunology Cancer
Indomethacin (Indometacin) sodium hydrateis a potent, orally active COX1/2 inhibitor with IC₅₀ values of 18 nM and 26 nM for COX-1 and COX-2, respectively. Indomethacin sodium hydrateis has anticancer activity and anti-infective activity. Indomethacin sodium hydrateis can be used for cancer, inflammation and viral infection research .

HY-106055

Murabutide	HIV	Inflammation/Immunology
Murabutide is a safe synthetic immunomodulator. Murabutide can reduce CD4 and CCR5 receptor expression and secrete high levels of beta-chemokines. Murabutide enhances nonspecific resistance against viral infections. Murabutide did not affect virus entry, reverse transcriptase activity or early proviral DNA formation in the cytoplasm of infected cells .

HY-155527

SARS-CoV-2 Mpro-IN-9	SARS-CoV	Infection
SARS-CoV-2 Mpro-IN-9 (compound c7) is a nonpeptidic, noncovalent SARS-CoV-2 M ^pro inhibitor (IC₅₀=0.085 μM), with improved physicochemical and drug metabolism and pharmacokinetics (DMPK) properties. SARS-CoV-2 Mpro-IN-9 inhibits viral replication (EC₅₀=1.10 μM) in SARS-CoV-2-infected Vero E6 cells, while exhibits low cytotoxic effects (CC₅₀>50 μM) .

HY-B0402S

Amantadine-d15 1-Adamantanamine-d₁₅; 1-Aminoadamantane-d₁₅	Influenza Virus Orthopoxvirus SARS-CoV Apoptosis	Infection Neurological Disease Cancer
Amantadine-d₁₅ is the deuterium labeled Amantadine. Amantadine (1-Adamantanamine) is an antiviral agent with activity against influenza A viruses. Amantadine blocks the proton flow through the M2 ion channel (M2 proton channel of influenza A) and thus prevents the release of viral RNA into the cytoplasm of the infected cells. Amantadine is an antiparkinsonian agent[1][2].

HY-14397S2

Indometacin-d7	Bacterial Influenza Virus Antibiotic COX Isotope-Labeled Compounds	Inflammation/Immunology Cancer
Indometacin-d₇ is deuterated labeled Indomethacin (HY-14397). Indomethacin (Indometacin) is a potent, orally active COX1/2 inhibitor with IC₅₀ values of 18 nM and 26 nM for COX-1 and COX-2, respectively. Indomethacin has anticancer activity and anti-infective activity. Indomethacin can be used for cancer, inflammation and viral infection research .

HY-14397G

Indomethacin Indometacin	Antibiotic Influenza Virus Bacterial COX	Cancer
Indomethacin (GMP) is Indomethacin (HY-14397) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. Indomethacin (Indometacin) is a potent, orally active COX1/2 inhibitor with IC₅₀ values of 18 nM and 26 nM for COX-1 and COX-2, respectively. Indomethacin has anticancer activity and anti-infective activity. Indomethacin can be used for cancer, inflammation and viral infection research .

HY-112163

Zotatifin 5 Publications Verification eFT226	Eukaryotic Initiation Factor (eIF) SARS-CoV Apoptosis	Infection Cancer
Zotatifin (eFT226) is a potent, selective, and well-tolerated eIF4A inhibitor. Zotatifin promotes eIF4A binding to specific mRNA sequences with recognition motifs in the 5’-UTRs (IC₅₀=2 nM) and interferes with the assembly of the eIF4F initiation complex . Zotatifin shows robust antiviral effects, it effectively reduces viral infectivity by inhibiting SARS-CoV-2 NP protein biogenesis (IC₉₀=37 nM) . Zotatifin induces cell apoptosis .

HY-149058

Neuraminidase-IN-13	Influenza Virus	Infection
Neuraminidase-IN-13 (Compound 10) is a neuraminidase inhibitor with antiviral activity and low cytotoxicity. Neuraminidase-IN-13 significantly inhibits NDV infection of Vero cells by preventing the release of viral particles from infected cells . Neuraminidase-IN-13 is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. Strain-promoted alkyne-azide cycloaddition (SPAAC) can also occur with molecules containing DBCO or BCN groups.

HY-12946A

BI 653048 phosphate	Glucocorticoid Receptor Cytochrome P450 HCV Protease	Infection Inflammation/Immunology
BI 653048 phosphate is a selective and orally active nonsteroidal glucocorticoid (GC) agonist with an IC₅₀ value of 55 nM . BI 653048 phosphate inhibits CP1A2, CYP2D6, CYP2C9, CYP2C19 and CYP3A4 isoforms’ activity and reduces affinity for the hERG ion channel (IC₅₀>30 μM) . BI 653048 phosphate is extracted from patent WO2005028501A1 (Compound 103), is also a HCV NS3 protease inhibitor that can reduce viral loads infected with the hepatitis C virus .

HY-12946

BI 653048	Glucocorticoid Receptor Cytochrome P450 HCV Protease	Infection Inflammation/Immunology
BI 653048 is a selective and orally active nonsteroidal glucocorticoid (GC) agonist with an IC₅₀ value of 55 nM . BI 653048 inhibits CP1A2, CYP2D6, CYP2C9, CYP2C19 and CYP3A4 isoforms’ activity and reduces affinity for the hERG ion channel (IC₅₀>30 μM) . BI 653048 is extracted from patent WO2005028501A1 (Compound 103), is also a HCV NS3 protease inhibitor that can reduce viral loads infected with the hepatitis C virus .

HY-144668

RdRP-IN-4	Influenza Virus	Infection
RdRP-IN-4 (compound 11q), an aryl benzoyl hydrazide analog, is an orally active influenza A virus RNA-dependent RNA polymerase (RdRp) inhibitor by interacting with the PB1 subunit. RdRP-IN-4 exhibits potent inhibitory activity against the avian H5N1 flu strain with an EC50 of 18 nM in MDCK cells. RdRP-IN-4 displays excellent potency against the the H1N1 (A/PR/8/34) Flu A strain and Flu B strain (B/Lee/1940) with EC50 values of 53 nM and 20 nM, respectively. RdRP-IN-4 significantly inhibits the expression level of viral nucleoprotein (NP) in a dose-dependent manner. RdRP-IN-4 exhibits significant antiviral activity in infected mice .

Cat. No.	Product Name

HY-L002

Anti-Infection Compound Library	2,900 compounds
An infection occurs when another organism enters a person’s body and causes disease. The organisms that cause infections are very diverse and can include things like viruses, bacteria, fungi, and parasites. The immune system is an effective barrier against infectious agents. MCE provides a unique collection of 2,900 anti-infective compounds with anti-bacterial, anti-viral, anti-fungal and anti-parasite activities that can be used for drug screening and other research in anti-microbial area.

Anti-Infection Compound Library

2,900 compounds

An infection occurs when another organism enters a person’s body and causes disease. The organisms that cause infections are very diverse and can include things like viruses, bacteria, fungi, and parasites. The immune system is an effective barrier against infectious agents.

MCE provides a unique collection of 2,900 anti-infective compounds with anti-bacterial, anti-viral, anti-fungal and anti-parasite activities that can be used for drug screening and other research in anti-microbial area.

HY-L073

Anti-Hepatitis C Virus Compound Library	283 compounds
Hepatitis C virus (HCV) is a hepatotropic enveloped positive- strand RNA virus (family Flaviviridae) that infects the parenchymal cells of the liver. HCV infection is a significant public health burden. Globally, an estimated 71 million people have chronic hepatitis C virus infection. A significant number of those who are chronically infected will develop cirrhosis or liver cancer. To date, there is no vaccine against HCV, and combination pegylated alpha interferon (pIFN-) and ribavirin, the main standard-of-care treatment for HCV, is effective in only a subset of patients and is associated with a wide spectrum of toxic side effects and complications. More recently, new therapeutic approaches that target essential components of the HCV life cycle have been developed, including direct-acting antiviral (DAA) that specifically block a viral enzyme or functional protein and host-targeted agents (HTA) that block interactions between host proteins and viral components that are essential to the viral life cycle. However, the genetic diversity of HCV viruses and the stage of liver disease (i.e., cirrhosis) are revealing themselves as obstacles for effective, pan-genotypic treatments. There still exists a need for the discovery and development of new HCV inhibitors. In particular, since the future of HCV therapy will likely consist of a cocktail approach using multiple inhibitors that target different steps of infection, new antivirals targeting all steps of the viral infection cycle. MCE offers a unique collection of 283 compounds with identified and potential anti-HCV activity. MCE Anti- Hepatitis C Virus Compound Library is a useful tool for discovery new anti-HCV drugs and other anti-infection research.

Anti-Hepatitis C Virus Compound Library

283 compounds

Hepatitis C virus (HCV) is a hepatotropic enveloped positive- strand RNA virus (family Flaviviridae) that infects the parenchymal cells of the liver. HCV infection is a significant public health burden. Globally, an estimated 71 million people have chronic hepatitis C virus infection. A significant number of those who are chronically infected will develop cirrhosis or liver cancer. To date, there is no vaccine against HCV, and combination pegylated alpha interferon (pIFN-) and ribavirin, the main standard-of-care treatment for HCV, is effective in only a subset of patients and is associated with a wide spectrum of toxic side effects and complications. More recently, new therapeutic approaches that target essential components of the HCV life cycle have been developed, including direct-acting antiviral (DAA) that specifically block a viral enzyme or functional protein and host-targeted agents (HTA) that block interactions between host proteins and viral components that are essential to the viral life cycle. However, the genetic diversity of HCV viruses and the stage of liver disease (i.e., cirrhosis) are revealing themselves as obstacles for effective, pan-genotypic treatments. There still exists a need for the discovery and development of new HCV inhibitors. In particular, since the future of HCV therapy will likely consist of a cocktail approach using multiple inhibitors that target different steps of infection, new antivirals targeting all steps of the viral infection cycle.

MCE offers a unique collection of 283 compounds with identified and potential anti-HCV activity. MCE Anti- Hepatitis C Virus Compound Library is a useful tool for discovery new anti-HCV drugs and other anti-infection research.

Indomethacin (GMP) Indometacin (GMP)	Fluorescent Dye
Indomethacin (GMP) is Indomethacin (HY-14397) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. Indomethacin (Indometacin) is a potent, orally active COX1/2 inhibitor with IC₅₀ values of 18 nM and 26 nM for COX-1 and COX-2, respectively. Indomethacin has anticancer activity and anti-infective activity. Indomethacin can be used for cancer, inflammation and viral infection research .

Indomethacin (GMP) Indometacin (GMP)	Biochemical Assay Reagents
Indomethacin (GMP) is Indomethacin (HY-14397) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. Indomethacin (Indometacin) is a potent, orally active COX1/2 inhibitor with IC₅₀ values of 18 nM and 26 nM for COX-1 and COX-2, respectively. Indomethacin has anticancer activity and anti-infective activity. Indomethacin can be used for cancer, inflammation and viral infection research .

Cat. No.	Product Name	Category	Target	Chemical Structure